You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVilazodone
Accession NumberDB06684
TypeSmall Molecule
GroupsApproved
Description

Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT receptors. It has been shown to be equally efficacious as other antidepressants with similar gastrointestinal side effects and possibly with reduced sexual side effects and weight gain. Vilazodone is an antidepressant agent that can used as an alternative for patients who cannot tolerate therapy with other antidepressant classes such as selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors. Treatment should be titrated towards the target dose, which is 40mg per day.

Structure
Thumb
Synonyms
Vilazodona
Vilazodonum
External Identifiers
  • EMD-68843
  • SB 659746A
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ViibrydkitoralForest Laboratories, Inc.2011-04-29Not applicableUs
Viibrydtablet40 mg/1oralAvera Mc Kennan Hospital2015-03-10Not applicableUs
Viibrydtablet40 mg/1oralCardinal Health2011-04-29Not applicableUs
Viibrydtablet40 mg/1oralForest Laboratories, Inc.2011-04-29Not applicableUs
Viibrydtablet40 mgoralForest Laboratories Canada IncNot applicableNot applicableCanada
Viibrydtablet20 mg/1oralForest Laboratories, Inc.2011-04-29Not applicableUs
Viibrydtablet20 mgoralForest Laboratories Canada IncNot applicableNot applicableCanada
Viibrydtablet10 mg/1oralForest Laboratories, Inc.2011-04-29Not applicableUs
Viibrydtablet10 mgoralForest Laboratories Canada IncNot applicableNot applicableCanada
ViibrydkitoralForest Laboratories, Inc.2011-04-29Not applicableUs
Viibrydtablet10 mg/1oralAvera Mc Kennan Hospital2015-03-03Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
ViibrydForest Laboratories Canada Inc
Salts
Name/CASStructureProperties
Vilazodone hydrochloride
163521-08-2
Thumb
  • InChI Key: RPZBRGFNBNQSOP-UHFFFAOYSA-N
  • Monoisotopic Mass: 477.193152872
  • Average Mass: 477.986
DBSALT000187
Categories
UNIIS239O2OOV3
CAS number163521-12-8
WeightAverage: 441.5249
Monoisotopic: 441.216475133
Chemical FormulaC26H27N5O2
InChI KeyInChIKey=SGEGOXDYSFKCPT-UHFFFAOYSA-N
InChI
InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)
IUPAC Name
5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide
SMILES
NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Indole or derivatives
  • Indole
  • Benzofuran
  • Dialkylarylamine
  • Benzonitrile
  • Aralkylamine
  • N-alkylpiperazine
  • Benzenoid
  • Substituted pyrrole
  • Heteroaromatic compound
  • Pyrrole
  • Furan
  • Tertiary aliphatic amine
  • Tertiary amine
  • Primary carboxylic acid amide
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Nitrile
  • Carbonitrile
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationVilazodone is approved for treatment of acute episodes of major depression. Labeling of vilazodone describes an increased risk of suicidal thoughts in children, adolescents and young adults. The use of vilazodone in pediatrics is not indicated. Its use with monoamine oxidase inhibitors (MAOI) is contraindicated due to increased risk of serotonin syndome. Once the MAOI is discontinued, a 14-day washout period must pass before starting vilazodone.
PharmacodynamicsVilazodone increases serotonin levels in the brain by inhibiting the reuptake of serotonin while acting as a partial agonist on serotonin-1A receptors. It has therefore been coined by scientists as a selective partial agonist and reuptake inhibitor (SPARI). Because of its partial agonist activity for serotonin-1A, vilazodone helps to reduce anxiety.
Mechanism of actionSince serotonin is believed to be one of the three main neurotransmitters that is low or imbalanced in patients with depression- pathways seeking to increase serotonin levels are targeted by pharmaceutical companies. As a selective serotonin reuptake inhibitor, vilazodone prevents serotonin from re-entering cell bodies. Hence, they will remain longer in the synapse. Vilazodone also has an inherent selectivity for serotonin-1A receptors, acting as a partial agonist which stimulates the production of serotonin. The end result is increased serotonin in the synaptic cleft, allowing serotonin to resume its action on nearby cells. The mechanism of the antidepressant effect of vilazodone is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake.
Related Articles
AbsorptionVilazodone's absorption is improved when taken with food to 72%.
Volume of distributionNot Available
Protein binding96-99% protein bound
Metabolism

Major: CYP3A4. Minor: CYP2C19 and CYP2D6

Route of elimination1% recovered in urine. 2% unchanged in feces.
Half life25.4h
Clearance

21.1L/h

ToxicityVomiting, serotonin syndrome.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9959
Blood Brain Barrier+0.9694
Caco-2 permeable-0.6764
P-glycoprotein substrateSubstrate0.6362
P-glycoprotein inhibitor IInhibitor0.581
P-glycoprotein inhibitor IIInhibitor0.9022
Renal organic cation transporterNon-inhibitor0.527
CYP450 2C9 substrateNon-substrate0.9138
CYP450 2D6 substrateNon-substrate0.5431
CYP450 3A4 substrateSubstrate0.5983
CYP450 1A2 substrateNon-inhibitor0.5637
CYP450 2C9 inhibitorInhibitor0.5397
CYP450 2D6 inhibitorNon-inhibitor0.7021
CYP450 2C19 inhibitorInhibitor0.6998
CYP450 3A4 inhibitorNon-inhibitor0.6258
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8731
Ames testNon AMES toxic0.6088
CarcinogenicityNon-carcinogens0.9181
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6208 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8967
hERG inhibition (predictor II)Inhibitor0.87
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Kitoral
Kit; tabletoral
Tabletoral10 mg
Tabletoral10 mg/1
Tabletoral20 mg
Tabletoral20 mg/1
Tabletoral40 mg
Tabletoral40 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5532241 No1999-09-292019-09-29Us
US7834020 No2002-06-052022-06-05Us
US8193195 No2002-06-052022-06-05Us
US8236804 No2002-06-052022-06-05Us
US8673921 No2002-06-052022-06-05Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityAqueous solubility is 0.32 mg/mLNot Available
pKa7.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.123 mg/mLALOGPS
logP4.21ALOGPS
logP3.72ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)14.19ChemAxon
pKa (Strongest Basic)8.6ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area102.29 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity129.71 m3·mol-1ChemAxon
Polarizability50.02 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR: A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011 Apr;72(4):441-7. doi: 10.4088/JCP.10m06596. [PubMed:21527122 ]
  2. Traynor K: Vilazodone approved for major depression. Am J Health Syst Pharm. 2011 Mar 1;68(5):366. doi: 10.2146/news110009. [PubMed:21330672 ]
  3. Howland RH: Vilazodone: another novel atypical antidepressant drug. J Psychosoc Nurs Ment Health Serv. 2011 Mar;49(3):19-22. doi: 10.3928/02793695-20110203-98. Epub 2011 Feb 16. [PubMed:21323263 ]
  4. Dawson LA, Watson JM: Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther. 2009 Summer;15(2):107-17. [PubMed:19499624 ]
  5. de Paulis T: Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs. 2007 Mar;10(3):193-201. [PubMed:17351874 ]
  6. Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I: Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7. [PubMed:12183683 ]
  7. Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU: A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract. 2013 Aug;17(3):160-9. doi: 10.3109/13651501.2013.794245. Epub 2013 May 29. [PubMed:23578403 ]
  8. Dopheide JA: Vilazodone's comparative merits yet to be demonstrated. Am J Health Syst Pharm. 2012 Sep 15;69(18):1549. doi: 10.2146/ajhp110570. [PubMed:22935936 ]
External Links
ATC CodesN06AX24
AHFS Codes
  • 28:16.04.24
PDB EntriesNot Available
FDA labelDownload (164 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabVilazodone may increase the anticoagulant activities of Abciximab.
AcenocoumarolVilazodone may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Acetophenazine.
Acetylsalicylic acidVilazodone may increase the antiplatelet activities of Acetylsalicylic acid.
AlteplaseVilazodone may increase the anticoagulant activities of Alteplase.
AmisulprideThe risk or severity of adverse effects can be increased when Vilazodone is combined with Amisulpride.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Vilazodone.
AnistreplaseVilazodone may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Vilazodone is combined with Apixaban.
AprepitantThe serum concentration of Vilazodone can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Vilazodone.
AtazanavirThe serum concentration of Vilazodone can be increased when it is combined with Atazanavir.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Vilazodone.
BenzquinamideThe risk or severity of adverse effects can be increased when Vilazodone is combined with Benzquinamide.
BexaroteneThe serum concentration of Vilazodone can be decreased when it is combined with Bexarotene.
BoceprevirThe serum concentration of Vilazodone can be increased when it is combined with Boceprevir.
BosentanThe serum concentration of Vilazodone can be decreased when it is combined with Bosentan.
BuspironeBuspirone may increase the serotonergic activities of Vilazodone.
CarbamazepineThe serum concentration of Vilazodone can be decreased when it is combined with Carbamazepine.
CarphenazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Carphenazine.
CeritinibThe serum concentration of Vilazodone can be increased when it is combined with Ceritinib.
ChlormezanoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Chlorprothixene.
CimetidineThe metabolism of Vilazodone can be decreased when combined with Cimetidine.
Citric AcidVilazodone may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Vilazodone can be increased when it is combined with Clarithromycin.
ClozapineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Clozapine.
CobicistatThe serum concentration of Vilazodone can be increased when it is combined with Cobicistat.
CollagenaseThe risk or severity of adverse effects can be increased when Vilazodone is combined with Collagenase.
ConivaptanThe serum concentration of Vilazodone can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Vilazodone can be increased when it is combined with Crizotinib.
CyproheptadineThe therapeutic efficacy of Vilazodone can be decreased when used in combination with Cyproheptadine.
Dabigatran etexilateVilazodone may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Vilazodone can be decreased when it is combined with Dabrafenib.
DalteparinVilazodone may increase the anticoagulant activities of Dalteparin.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Vilazodone.
DarunavirThe serum concentration of Vilazodone can be increased when it is combined with Darunavir.
DasatinibDasatinib may increase the anticoagulant activities of Vilazodone.
DeferasiroxThe serum concentration of Vilazodone can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Vilazodone can be increased when it is combined with Delavirdine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Vilazodone is combined with Deoxycholic Acid.
DesmopressinThe risk or severity of adverse effects can be increased when Vilazodone is combined with Desmopressin.
DextromethorphanVilazodone may increase the serotonergic activities of Dextromethorphan.
DicoumarolVilazodone may increase the anticoagulant activities of Dicoumarol.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Vilazodone.
DiltiazemThe serum concentration of Vilazodone can be increased when it is combined with Diltiazem.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Vilazodone.
DronedaroneThe serum concentration of Vilazodone can be increased when it is combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Vilazodone is combined with Droperidol.
Edetic AcidVilazodone may increase the anticoagulant activities of Edetic Acid.
EnoxaparinVilazodone may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Vilazodone can be decreased when it is combined with Enzalutamide.
ErythromycinThe serum concentration of Vilazodone can be increased when it is combined with Erythromycin.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Vilazodone.
Ethyl biscoumacetateVilazodone may increase the anticoagulant activities of Ethyl biscoumacetate.
FencamfamineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Fencamfamine.
FluconazoleThe serum concentration of Vilazodone can be increased when it is combined with Fluconazole.
FlupentixolThe risk or severity of adverse effects can be increased when Vilazodone is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Fluspirilene.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Vilazodone.
Fondaparinux sodiumVilazodone may increase the anticoagulant activities of Fondaparinux sodium.
FosamprenavirThe serum concentration of Vilazodone can be increased when it is combined with Fosamprenavir.
FosphenytoinThe serum concentration of Vilazodone can be decreased when it is combined with Fosphenytoin.
GalantamineThe metabolism of Galantamine can be decreased when combined with Vilazodone.
GlucosamineGlucosamine may increase the antiplatelet activities of Vilazodone.
GranisetronGranisetron may increase the serotonergic activities of Vilazodone.
HaloperidolThe risk or severity of adverse effects can be increased when Vilazodone is combined with Haloperidol.
HeparinVilazodone may increase the anticoagulant activities of Heparin.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Vilazodone.
IcosapentVilazodone may increase the antiplatelet activities of Icosapent.
IdelalisibThe serum concentration of Vilazodone can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of Vilazodone can be increased when it is combined with Imatinib.
IndinavirThe serum concentration of Vilazodone can be increased when it is combined with Indinavir.
Insulin HumanVilazodone may increase the hypoglycemic activities of Insulin Regular.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Vilazodone.
Ioflupane I 123Vilazodone may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IsavuconazoniumThe serum concentration of Vilazodone can be increased when it is combined with Isavuconazonium.
ItraconazoleThe serum concentration of Vilazodone can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Vilazodone can be increased when it is combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Vilazodone.
LimaprostLimaprost may increase the antiplatelet activities of Vilazodone.
LinezolidLinezolid may increase the serotonergic activities of Vilazodone.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Vilazodone.
LithiumLithium may increase the serotonergic activities of Vilazodone.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Vilazodone.
LoxapineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Loxapine.
MesoridazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Mesoridazine.
MethadoneThe metabolism of Methadone can be decreased when combined with Vilazodone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Methotrimeprazine.
Methylene blueVilazodone may increase the serotonergic activities of Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Vilazodone.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Vilazodone.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Vilazodone.
MifepristoneThe serum concentration of Vilazodone can be increased when it is combined with Mifepristone.
MitotaneThe serum concentration of Vilazodone can be decreased when it is combined with Mitotane.
MolindoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Molindone.
MorphineMorphine may increase the serotonergic activities of Vilazodone.
NefazodoneThe serum concentration of Vilazodone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Vilazodone can be increased when it is combined with Nelfinavir.
NilotinibThe serum concentration of Vilazodone can be increased when it is combined with Nilotinib.
ObinutuzumabThe risk or severity of adverse effects can be increased when Vilazodone is combined with Obinutuzumab.
OlanzapineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Olanzapine.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Vilazodone.
OndansetronThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ondansetron.
PaliperidoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Paliperidone.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Vilazodone.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Vilazodone.
PerphenazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Perphenazine.
PhenelzinePhenelzine may increase the serotonergic activities of Vilazodone.
PhenindioneVilazodone may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Vilazodone can be decreased when it is combined with Phenobarbital.
PhenprocoumonVilazodone may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Vilazodone can be decreased when it is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Vilazodone is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Piperacetazine.
PosaconazoleThe serum concentration of Vilazodone can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Vilazodone can be decreased when it is combined with Primidone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Promazine.
QuetiapineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Quetiapine.
RemoxiprideThe risk or severity of adverse effects can be increased when Vilazodone is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Reserpine.
ReteplaseVilazodone may increase the anticoagulant activities of Reteplase.
RidogrelVilazodone may increase the anticoagulant activities of Ridogrel.
RifabutinThe serum concentration of Vilazodone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Vilazodone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Vilazodone can be decreased when it is combined with Rifapentine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Vilazodone.
RitonavirThe serum concentration of Vilazodone can be increased when it is combined with Ritonavir.
RivaroxabanVilazodone may increase the anticoagulant activities of Rivaroxaban.
SaquinavirThe serum concentration of Vilazodone can be increased when it is combined with Saquinavir.
SertindoleThe risk or severity of adverse effects can be increased when Vilazodone is combined with Sertindole.
SiltuximabThe serum concentration of Vilazodone can be decreased when it is combined with Siltuximab.
St. John's WortThe serum concentration of Vilazodone can be decreased when it is combined with St. John's Wort.
StreptokinaseVilazodone may increase the anticoagulant activities of Streptokinase.
SulodexideVilazodone may increase the anticoagulant activities of Sulodexide.
SulpirideThe risk or severity of adverse effects can be increased when Vilazodone is combined with Sulpiride.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Vilazodone.
TelaprevirThe serum concentration of Vilazodone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Vilazodone can be increased when it is combined with Telithromycin.
TenecteplaseVilazodone may increase the anticoagulant activities of Tenecteplase.
ThioridazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Thiothixene.
TipranavirTipranavir may increase the antiplatelet activities of Vilazodone.
TocilizumabThe serum concentration of Vilazodone can be decreased when it is combined with Tocilizumab.
TositumomabThe risk or severity of adverse effects can be increased when Vilazodone is combined with Tositumomab.
TramadolVilazodone may increase the neuroexcitatory activities of Tramadol.
TranylcypromineTranylcypromine may increase the serotonergic activities of Vilazodone.
TrazodoneVilazodone may increase the serotonergic activities of Trazodone.
TreprostinilVilazodone may increase the anticoagulant activities of Treprostinil.
TrichlormethiazideVilazodone may increase the activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Triflupromazine.
UrokinaseVilazodone may increase the anticoagulant activities of Urokinase.
VerapamilThe serum concentration of Vilazodone can be increased when it is combined with Verapamil.
Vitamin EVitamin E may increase the antiplatelet activities of Vilazodone.
VoriconazoleThe serum concentration of Vilazodone can be increased when it is combined with Voriconazole.
WarfarinVilazodone may increase the anticoagulant activities of Warfarin.
ZiprasidoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ziprasidone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Vilazodone is combined with Zuclopenthixol.
Food Interactions
  • Caution taking vilazodone with foods/herbal product with antiplatelet/anticoagulant properties
  • Gingko bilboa, ginger, garlic, green tea, licorice, horseradish

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I: Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7. [PubMed:12183683 ]
  2. Adamec R, Bartoszyk GD, Burton P: Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol. 2004 Nov 3;504(1-2):65-77. [PubMed:15507223 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Link [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I: Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7. [PubMed:12183683 ]
  2. Adamec R, Bartoszyk GD, Burton P: Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol. 2004 Nov 3;504(1-2):65-77. [PubMed:15507223 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:49 / Updated on August 24, 2016 01:52